CorMedix Inc. beat EPS estimates 69% of the time across 16 reported quarters (11 beats, 5 misses), averaging +9.8% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $0.26 | $0.29 | +11.5% | Beat | |
| Q1 FY26 | $0.35 | $0.43 | +22.9% | Beat | |
| Q4 FY25 | $0.86 | $0.61 | -29.1% | Miss | Q4 FY25 call |
| Q3 FY25 | $0.48 | $0.57 | +18.8% | Beat | |
| Q2 FY25 | $0.20 | $0.28 | +40.0% | Beat | |
| Q1 FY25 | $0.25 | $0.30 | +20.0% | Beat | |
| Q4 FY24 | $0.17 | $0.22 | +29.4% | Beat | |
| Q3 FY24 | $-0.10 | $-0.05 | +50.0% | Beat | |
| Q2 FY24 | $-0.26 | $-0.25 | +3.9% | Beat | |
| Q1 FY24 | $-0.27 | $-0.25 | +7.4% | Beat | |
| Q4 FY23 | $-0.21 | $-0.26 | -23.8% | Miss | |
| Q3 FY23 | $-0.21 | $-0.17 | +19.1% | Beat |
Back to CRMD overview · CRMD holders · CRMD KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.